Fosun International Garners Five Awards from Corporate Governance Asia
Fosun International (OTC:FOSUY) has received five prestigious awards from Corporate Governance Asia, including recognition for its Co-CEOs and corporate sustainability efforts. Executive Directors and Co-CEOs Chen Qiyu and Xu Xiaoliang were both honored with Asia's Best CEO awards, while the company secured the Sustainable Asia Award 2025, Best Environmental Responsibility Award, and Best Corporate Communications Award.
The company has demonstrated significant achievements in ESG initiatives, maintaining an MSCI ESG rating of AA and ranking in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment. Fosun has committed to reaching carbon neutrality by 2050 and achieving peak carbon emissions by 2028.
In healthcare innovation, the company reported that its drug HANSIZHUANG received European Union approval in early 2025 as the first PD-1 innovative drug for first-line treatment of extensive-stage small cell lung cancer. Additionally, Fosun's artesunate injection has treated over 80 million severe malaria patients globally, while its CAR-T cell therapy has benefited more than 800 lymphoma patients in mainland China.
Fosun International (OTC:FOSUY) ha ricevuto cinque prestigiosi riconoscimenti da Corporate Governance Asia, inclusi premi per i suoi Co-CEO e per gli sforzi nella sostenibilità aziendale. I Direttori Esecutivi e Co-CEO Chen Qiyu e Xu Xiaoliang sono stati entrambi premiati come i migliori CEO dell'Asia, mentre l'azienda ha ottenuto il Sustainable Asia Award 2025, il premio per la migliore responsabilità ambientale e il premio per le migliori comunicazioni aziendali.
L'azienda ha dimostrato risultati significativi nelle iniziative ESG, mantenendo un rating MSCI ESG di AA e posizionandosi nel top 5% tra i pari a livello globale nella Corporate Sustainability Assessment di S&P Global. Fosun si è impegnata a raggiungere la neutralità carbonica entro il 2050 e il picco delle emissioni di carbonio entro il 2028.
Nel campo dell'innovazione sanitaria, l'azienda ha annunciato che il suo farmaco HANSIZHUANG ha ottenuto l'approvazione dell'Unione Europea all'inizio del 2025 come primo farmaco innovativo PD-1 per il trattamento di prima linea del carcinoma polmonare a piccole cellule in stadio esteso. Inoltre, l'iniezione di artesunato di Fosun ha trattato oltre 80 milioni di pazienti con malaria grave a livello globale, mentre la terapia con cellule CAR-T ha beneficiato più di 800 pazienti con linfoma nella Cina continentale.
Fosun International (OTC:FOSUY) ha recibido cinco prestigiosos premios de Corporate Governance Asia, incluyendo reconocimientos para sus Co-CEOs y sus esfuerzos en sostenibilidad corporativa. Los Directores Ejecutivos y Co-CEOs Chen Qiyu y Xu Xiaoliang fueron galardonados con los premios a los mejores CEO de Asia, mientras que la compañía obtuvo el Premio Asia Sostenible 2025, el Premio a la Mejor Responsabilidad Ambiental y el Premio a la Mejor Comunicación Corporativa.
La empresa ha demostrado logros significativos en iniciativas ESG, manteniendo una calificación MSCI ESG de AA y situándose en el top 5% entre sus pares globales en la Evaluación de Sostenibilidad Corporativa de S&P Global. Fosun se ha comprometido a alcanzar la neutralidad de carbono para 2050 y a lograr el pico de emisiones de carbono para 2028.
En innovación en salud, la compañía informó que su medicamento HANSIZHUANG recibió la aprobación de la Unión Europea a principios de 2025 como el primer fármaco innovador PD-1 para el tratamiento de primera línea del cáncer de pulmón de células pequeñas en etapa extensa. Además, la inyección de artesunato de Fosun ha tratado a más de 80 millones de pacientes con malaria grave en todo el mundo, mientras que su terapia con células CAR-T ha beneficiado a más de 800 pacientes con linfoma en China continental.
Fosun International (OTC:FOSUY)는 Corporate Governance Asia로부터 다섯 개의 권위 있는 상을 받았으며, 공동 CEO들과 기업의 지속 가능성 노력에 대한 인정도 포함되어 있습니다. 전무이사이자 공동 CEO인 Chen Qiyu와 Xu Xiaoliang는 아시아 최고의 CEO 상을 수상했으며, 회사는 2025년 지속 가능한 아시아 상, 최고의 환경 책임상, 최고의 기업 커뮤니케이션 상을 획득했습니다.
회사는 ESG 이니셔티브에서 뛰어난 성과를 보였으며, MSCI ESG 등급 AA를 유지하고 S&P Global의 기업 지속 가능성 평가에서 글로벌 동료 중 상위 5%에 랭크되었습니다. Fosun은 2050년까지 탄소 중립 달성과 2028년까지 탄소 배출 정점을 달성하겠다는 목표를 세웠습니다.
의료 혁신 분야에서, 회사는 자사의 약물 HANSIZHUANG이 2025년 초 유럽 연합 승인을 받았으며 이는 진행성 소세포폐암 1차 치료를 위한 최초의 PD-1 혁신 약물입니다. 또한 Fosun의 아르테수네이트 주사는 전 세계적으로 8천만 명 이상의 중증 말라리아 환자를 치료했으며, CAR-T 세포 치료는 중국 본토에서 800명 이상의 림프종 환자에게 혜택을 주었습니다.
Fosun International (OTC:FOSUY) a reçu cinq prestigieux prix de Corporate Governance Asia, dont une reconnaissance pour ses co-CEO et ses efforts en matière de durabilité d'entreprise. Les directeurs exécutifs et co-CEO Chen Qiyu et Xu Xiaoliang ont tous deux été honorés avec les prix du meilleur CEO d'Asie, tandis que la société a obtenu le Sustainable Asia Award 2025, le prix de la meilleure responsabilité environnementale et le prix de la meilleure communication d'entreprise.
L'entreprise a démontré des réalisations significatives dans les initiatives ESG, maintenant une note MSCI ESG de AA et se classant parmi les 5 % meilleurs au niveau mondial selon l'évaluation de la durabilité d'entreprise de S&P Global. Fosun s'est engagée à atteindre la neutralité carbone d'ici 2050 et à atteindre le pic des émissions de carbone d'ici 2028.
En matière d'innovation en santé, la société a indiqué que son médicament HANSIZHUANG avait reçu l'approbation de l'Union européenne début 2025 en tant que premier médicament innovant PD-1 pour le traitement de première ligne du cancer du poumon à petites cellules étendu. De plus, l'injection d'artésunate de Fosun a traité plus de 80 millions de patients atteints de paludisme sévère dans le monde, tandis que sa thérapie par cellules CAR-T a bénéficié à plus de 800 patients atteints de lymphome en Chine continentale.
Fosun International (OTC:FOSUY) hat fünf renommierte Auszeichnungen von Corporate Governance Asia erhalten, darunter Anerkennungen für seine Co-CEOs und seine Unternehmensnachhaltigkeitsbemühungen. Die geschäftsführenden Direktoren und Co-CEOs Chen Qiyu und Xu Xiaoliang wurden beide mit den Asia's Best CEO Awards ausgezeichnet, während das Unternehmen den Sustainable Asia Award 2025, den Best Environmental Responsibility Award und den Best Corporate Communications Award erhielt.
Das Unternehmen hat bedeutende Erfolge bei ESG-Initiativen gezeigt, hält ein MSCI ESG-Rating von AA und gehört laut der Corporate Sustainability Assessment von S&P Global zu den Top 5 % der globalen Wettbewerber. Fosun hat sich verpflichtet, bis 2050 Kohlenstoffneutralität zu erreichen und den Höhepunkt der CO2-Emissionen bis 2028 zu erreichen.
Im Bereich der Gesundheitsinnovation berichtete das Unternehmen, dass sein Medikament HANSIZHUANG Anfang 2025 die Zulassung der Europäischen Union erhalten hat und das erste innovative PD-1-Medikament für die Erstlinienbehandlung des ausgedehnten kleinzelligen Lungenkarzinoms ist. Zudem hat Fosuns Artesunat-Injektion weltweit über 80 Millionen schwere Malariapatienten behandelt, während die CAR-T-Zelltherapie mehr als 800 Lymphompatienten in Festlandchina zugutekam.
- Maintained MSCI ESG rating of AA and ranked in top 5% among global peers in S&P Global's Corporate Sustainability Assessment
- Received EU approval for HANSIZHUANG as first PD-1 drug for ES-SCLC treatment
- Artesunate injection has treated over 80 million severe malaria patients globally
- Yi Kai Da CAR-T cell therapy has benefited over 800 lymphoma patients in mainland China
- Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families
- None.
Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International win
Fosun International receives Sustainable Asia Award 2025, Best Environmental Responsibility Award and Best Corporate Communications Award
Corporate Governance Asia is one of the most authoritative and influential corporate governance journals in the Asia Pacific region. The award recognizes outstanding industry leaders and enterprises that excelled in financial performance, corporate governance, corporate social responsibility, environmental protection, corporate communication and investor relations over the past year. Other award recipients of the 15th Asian Excellence Award include well-known Asia Pacific companies such as Sino Land, Sun Hung Kai Properties, Bank of China (
Recognizing Excellence in Business Performance and ESG Practices
According to Corporate Governance Asia, in 2024, in the face of the complex and volatile external environment, Fosun maintained its strategic focus on core businesses, achieved steady development, enhanced the operational capabilities of its key industries, and demonstrated strong operational resilience. Amid the complex external business environment, Mr. Chen Qiyu and Mr. Xu Xiaoliang, as the CEOs of a global large-scale private enterprise, have not only led the Group to grow its business operations, but also strengthened the management of sustainable development, proactively fulfilled corporate social responsibility, improved the Group's Environmental, Social, and Governance (ESG) performance, and leveraged the resources and advantages of Fosun's global industrial ecosystem to continuously create a better world. In recognition of these efforts, they were awarded the
Chen Qiyu, Executive Director and Co-CEO of Fosun International, said, "We are deeply honored to receive several prestigious awards from Corporate Governance Asia, including
Xu Xiaoliang, Executive Director and Co-CEO of Fosun International, said, "Globalization is the core of Fosun's development. Fosun has consistently leveraged global resources and combined global growth momentum with global resources, delivering more high-quality products and services to families around the world. With an increasingly sophisticated global business presence, Fosun operated responsibly across more than 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. As a global company rooted in
Advancing Global Sustainable Development with Outstanding ESG Performance
Corporate Governance Asia highlighted Fosun's unwavering commitment to advancing global ESG efforts. The Group has consistently strengthened its ESG framework, deepened its involvement in ESG initiatives, enhanced its climate resilience, and accelerated green development. Corporate Governance Asia highly commended Fosun's efforts in advancing ESG, noting that its initiatives not only inspire the industry but also reinforce
As a responsible global citizen, Fosun officially joined the United Nations Global Compact ("UN Global Compact") in 2014. It fully supports the ten principles of the UN Global Compact on human rights, labor, environment and anti-corruption, and has deeply integrated these principles into its "Create IMPACT" sustainable development strategy and code of conduct. Over the past year, despite the global environmental, social and economic uncertainties, Fosun remained committed to sustainable development, diligently upholding its long-term commitments in key areas of sustainable development, and achieving good results. Fosun International maintained an MSCI ESG rating of AA, achieved an HSI ESG rating of AA-, ranked in the top
Actively Responding to Climate Change and Promoting Low-carbon Transformation
Fosun actively responds to the national "dual carbon" goals by promoting carbon neutrality and energy conservation and emission reduction. In 2021, Fosun made a commitment to society – "strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050". Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement. As 2024 marked the final year before Hong Kong Stock Exchange's New Climate Requirements came into effect, Fosun International proactively aligned with international standards such as the Task Force on Climate-related Financial Disclosures (TCFD) recommendations and the International Financial Reporting Standards (IFRS) S2 Climate-related Disclosures Requirements, and released its third Climate Information Disclosures Report, enhancing the transparency of its climate actions and demonstrating its commitment to ongoing efforts in this area.
The Group also actively encourages its member companies to carry out climate actions. The Bund Finance Center (BFC), the Group's base in
In 2024, Fidelidade participated in the 29th session of the Conference of the Parties (
Leveraging Innovation to Actively Contribute to Society
Fosun adheres to the innovation-driven strategy, and the anticancer and antimalarial drugs developed by its health segment have widely benefited cancer patients and severe malaria patients. Henlius' innovative drug, HANSIZHUANG (serplulimab injection), an anti-PD-1 monoclonal antibody, was approved for marketing in the European Union in early 2025. This milestone makes it the first and only PD-1 innovative drug approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union. As of the end of 2024, Fosun Pharma's independently developed artesunate for injection had saved more than 80 million severe malaria patients worldwide, with more than 400 million doses supplied globally. In the Chinese mainland, Fosun Kairos' first CAR-T cell therapy product, Yi Kai Da (ejilunsai injection), had benefited over 800 lymphoma patients as of the end of 2024.
In order to better promote the fulfilment and implementation of corporate social responsibility, Fosun Foundation was established in 2012. It has been making unremitting efforts in the fields of global emergency relief, rural revitalization, health, education, culture and art, youth development, etc. to create social value. Among these initiatives, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families since its launch in 2017.
Looking ahead, Fosun remains dedicated to advancing its social responsibility through innovation and responsible global operations. Guided by its "Create IMPACT" sustainable development strategy, Fosun will intensify its efforts to build a more responsible, inclusive and sustainable future.
View original content:https://www.prnewswire.com/news-releases/fosun-international-garners-five-awards-from-corporate-governance-asia-302494128.html
SOURCE Fosun